Washington Trust Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Washington Trust Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11	Closed	-$3.48K	–	685
2023 Q4	$3.48K	Hold	11	–	–	﹤0.01%	609
2023 Q3	$1.86K	Hold	11	–	–	﹤0.01%	646
2023 Q2	$2.39K	Hold	11	–	–	﹤0.01%	619
2023 Q1	$2K	Hold	11	–	–	﹤0.01%	724
2022 Q4	$2.16K	Hold	11	–	–	﹤0.01%	719
2022 Q3	$2K	Sell	11 -8	-42%	-$1.62K	﹤0.01%	872
2022 Q2	$2K	Hold	19	–	–	﹤0.01%	901
2022 Q1	$2K	Buy	+19	New	+$2.14K	﹤0.01%	967

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Washington Trust Advisors's KRTX Position: Q1 2024 in Review

Washington Trust Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 11 shares — an estimated $3.48K sold.

Washington Trust Advisors first reported a position in KRTX in Q1 2022 and held it in 8 quarters. The position peaked at $3.48K in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Washington Trust Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Washington Trust Advisors sold 11 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.48K.
Washington Trust Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
Washington Trust Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $3.48K in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Washington Trust Advisors's 13F filing for Q1 2024, filed 7 May 2024.